Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.59 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589213 | 0.94 | ADORA2A (0.74) | ADORA2AADORA3ADORA1TMIGD3HTR2C | |
| SCHEMBL12060838 | 0.87 | ADORA1 (0.56) | ADORA2AADORA3ADORA1TMIGD3HTR2C | |
| SCHEMBL2811914 | 0.85 | ADORA1 (0.58) | ADORA2AADORA3ADORA1TMIGD3HTR2C | |
| SCHEMBL591555 | 0.85 | ADORA2A (0.84) | ADORA2AADORA3ADORA1 | |
| SCHEMBL1412223 | 0.84 | ADORA1 (0.65) | ADORA2AADORA3ADORA1TMIGD3HTR2C | |
| SCHEMBL4667586 | 0.84 | ADORA2A (0.61) | ADORA2AADORA3ADORA1 | |
| SCHEMBL591274 | 0.84 | ADORA2A (0.61) | ADORA2AADORA3ADORA1 | |
| SCHEMBL589461 | 0.84 | ADORA2A (0.61) | ADORA2AADORA3ADORA1 | |
| SCHEMBL591275 | 0.84 | ADORA2A (0.61) | ADORA2AADORA3ADORA1 | |
| Hydrochloric Acid SCHEMBL4226536 | 0.84 | ADORA1 (0.64) | ADORA2AADORA3ADORA1TMIGD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240680-A1 | Purine derivatives as a2a agonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.